User:Mr. Ibrahem/Sofosbuvir/daclatasvir

Daclatasvir/sofosbuvir (SOF/DCV), sold under the brand name Sovodak among others, is a combination medication used to treat hepatitis C. It is a first line treatment and is effective against all subtypes. It is more than 90% effective. It may be used in those who are at least 3 years old. It is generally take by mouth once per day for 12 weeks as either a single pill or separately.

Common side effects include headache, tiredness, nausea, and abdominal pain. Serious side effects are uncommon. Use of daclatasvir and sofosbuvir has not been found to be harmful in pregnancy but has not been well studied. It contains daclatasvir, a viral NS5A inhibitor, and sofosbuvir, a nucleotide inhibitor of the viral RNA polymerase NS5B.

It is the most commonly used treatment for hepatitis C in low and middle income countries as of 2022. The combination has never been approved in the United States and sale of daclatavir was stopped their in 2019. It is on the World Health Organization's List of Essential Medicines. It is the least expensive modern hepatitis C treatment, with costs from 50 to 1,400 USD.